Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1466-1471

  Norman, James ^a   Lopez, Jose ^a   Politz, Doug ^a  

^a Norman Parathyroid Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET;

ADULT; AGED; AMBULATORY SURGERY; ARTICLE; BONE ATROPHY; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOCALCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOPOROSIS; PARATHYROID FUNCTION; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; NAPHTHALENES; NAUSEA; OSTEOPOROSIS; TREATMENT FAILURE; VOMITING; YOUNG ADULT;

EID: 84862512192     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2065-9     Document Type: Article

References (21)

1. Nemeth EF, Steffry ME, Hammerland, LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040-5. (Pubitemid 28173250)
2. Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48:303-11.
3. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyper-parathyroidism. Trends Endocrinol Metab. 1999;10:66-71. (Pubitemid 29287825)
4. Urena P, Jacobson SH, Vervloet M, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant. 2009;24:2852-9.
5. Bover J, Aguilar A, Baas J, et al. Calcimimetics in the chronic kidney disease-mineral and bone disorder. Int J Artif Organs. 2009;32:108-21.
6. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. JCEM. 2003;88:5644-9. (Pubitemid 38033028)
7. Peacock M, Bilezikian JP, Klassen PS, Gou MD, Turner SA, Shoback D. Cinacalcet HCL maintains long-term normocalcemia in patients with primary hyperparathyroidism. JCEM. 2005;90: 135-41. (Pubitemid 40116646)
8. Marcocci C, Chanson P, Shoback D, Bilezikian J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. JCEM. 2009;94:2766-72.
9. Peacock M, Bolognese M, Borfsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. JCEM. 2009;94:4860-7.
10. Vasher M, Goodman A, Politz D, Norman J. Postoperative calcium requirements in 6000 patients undergoing outpatient parathyroidectomy: easily avoiding symptomatic hypocalcemia. J Am Coll Surg. 2010;211(1):49-54.
11. Norman J, Politz D. Measuring individual parathyroid gland hormone production in real-time during radioguided parathyroidectomy. Experience in over 8000 operations. Minerva Endocrinol. 2008,33;147-57.
12. Norman J, Goodman A, Politz D. Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10,000 cases. Endocr Pract. 2011;17:384-94.
13. Norman J, Politz D. 5000 parathyroid operations without frozen section or PTH assays: measuring individual parathyroid gland hormone production in real-time. Ann Surg Oncol. 2009;16(3):656-66.
14. Arranz Martin A, Villalon AA, Ramirez ML, et al. Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery. Endocrinol Nutr. 2011;58:24-31.
15. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCL reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96(1):E9-18.
16. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57:517-21. (Pubitemid 351317967)
17. Henschkowski J, Bischoff-Ferrari HA, Wuthrich RP, Serra AL. Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney Blood Press Res. 2011;34:97-103.
18. Borchhardt KA, Diarra D, Sulsbacher I, Benesch T, Haas M, Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010;31:482-9.
19. Borstnar S, Erzen B, Gmeiner ST, Kocjan T, Arnol M, Kandus A, Kovac D. Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients. Transpl Proc. 2010;42:4078-82.
20. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1315-22.
21. Schneider R, Kolios G, Koch BM, Fernandez ED, Bartsch DK, Schlosser K. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism-the German perspective. Surgery. 2010;148:1091-9.